Potent nucleoside and nucleotide analogs might replace hepatitis B immunoglobulin (HBIG) to prevent HBV recurrence after liver transplantation in HBV-related liver disease. Two studies, however, suggest that viral load before transplant, and not the HBIG regimen, is the strongest risk factor for HBV recurrence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Samuel, D. et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med. 329, 1842–1847 (1993).
Samuel, D. et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J. Hepatol. 45, 127–143 (2006).
Degertekin, B. et al. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am. J. Transplant. 10, 1823–1833 (2010).
Jiang, L. et al. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am. J. Transplant. 10, 1861–1869 (2010).
Coffin, C. S. et al. Virologic and clinical outcome of hepatitis B virus infection in HIV–HBV coinfected transplant recipients. Am. J. Transplant. 10, 1268–1275 (2010).
Faria, L. C. et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology 134, 1890–1899 (2008).
European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J. Hepatol. 50, 227–242 (2009).
Gane, E. J. et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 132, 931–937 (2007).
Buti, M. et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence Transplantation 84, 650–654 (2007).
Angus, P. W., Patterson, S. J., Strasser, S. I., McCaughan, G. W. & Gane, E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 48, 1460–1466 (2008).
Roche, B. et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology 38, 86–95 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Samuel is a consultant for Bristol–Myers Squibb, Gilead Sciences and Laboratoire Français du Fractionnement et des Biotechnologies. B. Roche declares no competing interests.
Rights and permissions
About this article
Cite this article
Roche, B., Samuel, D. Viral load predicts HBV recurrence after liver transplant. Nat Rev Gastroenterol Hepatol 7, 657–658 (2010). https://doi.org/10.1038/nrgastro.2010.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.165
